Last month, FDA finalized its recommendation on warning labels that Metformin is now OK for use with T2 patients with mild renal function impairment, and with some T2s with moderate renal function impairment:
It is a big deal because other commonly used T2 drugs (glipizide/glucotrol) may cause lows. Metformin doesn’t. So, for those patients with T2 diabetes who now have access to both, being able to switch to Metformin is a big progress. FDA announced the change in 2016 but finalized it in April 2017. Diatribe says this represents 1.6M patients: